Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 86, Issue 5, 2009, Pages 394-401

  Okada, Akinobu ^a,c   Noyori, Hiroko ^a   Yagen, Boris ^b   Shimshoni, Jakob Avi ^b   Bialer, Meir ^b   Fujiwara, Michio ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

EHU; EMPU; MBU; Neural tube defect; Skeletal malformation; Teratogenicity; Valproic acid; VCU

Indexed keywords

2 ETHYL 3 METHYLPENTANOYL UREA; 2 ETHYL 4 METHYLPENTANOYL UREA; 2 ETHYLHEXANOYL UREA; 2 METHYLBUTANOYL UREA; PENTETRAZOLE; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CESAREAN SECTION; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ELECTRIC SHOCK; FEMALE; FETUS; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEIZURE; SKELETON; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; BONE AND BONES; DEEP SEDATION; DIFFERENTIAL THRESHOLD; ELECTRIC STIMULATION; ELECTROSHOCK; FEMALE; FETAL DEATH; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NEURAL TUBE DEFECTS; PENTYLENETETRAZOLE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; TERATOGENS; UREA; VALPROIC ACID;

MUS;

EID: 70350704692     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20209     Document Type: Article

References (39)

1. Bialer M, Yagen B. 2007. Valproic acid: second generation. Neurotherapeutics 4:130-137.
2. Binkerd PE, Rowland JM, Nau H, Hendrickx AG. 1988. Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl Toxicol 11:485-493. (Pubitemid 18261931)
3. Bojic U, Elmazar MMA, Nau H. 1996. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 9:866-870. (Pubitemid 26250580)
4. Bojic U, Ehlers K, Ellerbeck U, Bacon CL, O'Driscoll E, O'Connell C, Berezin V, Kawa A, Lepekhin E, Bock E, Regan CM, Nau H. 1998. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre. Eur J Pharmacol 354:289-299. (Pubitemid 28401463)
5. Collins MD, Walling KM, Resnick E, Scott Jr WJ. 1991. The effect of administration time on malformations induced by three anti-convulsant agents in C57BL/6J mice with emphasis on forelimb ectrodactyly. Teratology 44:617-627.
6. Dansky LV, Finnell RH. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: human studies. Reprod Toxicol 5:301-335.
7. Finnell RH, Dansky LV. 1991. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod Toxicol 5:281-299.
8. Finnell RH, Bennett GD, Karras SB, Mohl VK. 1988. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-pentenoic acid metabolite. Teratology 38:313-320.
9. Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA. 1988. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology 38:329-345. (Pubitemid 18252455)
10. Isoherranen N,White HS, Finnell RH, Yagen B,Woodhead JH, Bennett GD, Wilcox KS, Barton ME, Bialer M. 2002. Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: A new antiepileptic drug. Epilepsia 43:115-126. (Pubitemid 34225991)
11. Isoherranen N, Yagen B, Bialer M. 2003. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol 16:203-211.
12. Kao J, Brown NA, Schmid B, Goulding EH, Fabro S. 1981. Teratogenicity of valproic acid: In vivo and in vitro investigations. Teratogenesis Carcinog Mutagen 1:367-382.
13. Kimmel CA, Trammell C. 1981. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol 56:271-273. (Pubitemid 12194038)
14. Levy RH, Shen DD, Abbott FS, RiggsW, Hacah H. 2002. Valproic acid chemistry, biotransformation and pharmacokinetics. In: Levy RH, Meldrum BS, Mattson RH, Perucca E, editors. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott. p 780-800, and other references cited therein.
15. Lindhout D, Schmidt D. 1986. In-utero exposure to valproate and neural tube defects. Lancet 1:1392-1393. (Pubitemid 16121930)
16. McNamara JO. 2006. Pharmacotherapy of the epilepsies. In: Brunton LL, Lazo JS, Parker KL, editor. The pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill. p 501-525.
17. Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E. 1996. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratogenesis Carcinog Mutagen 16:97-108. (Pubitemid 26308969)
18. Menegola E, Broccia ML, Prati M, Giavini E. 1998. Stage-dependent skeletal malformations induced by valproic acid in rat. Int J Dev Biol 42:99-102. (Pubitemid 28088198)
19. Nakatsuka T, Horimoto M, Ito M, Matsubara Y, Akaike M, Ariyuki F. 1997. Japan Pharmaceutical Manufacturers Association (JPMA) survey on background control data of developmental and reproductive toxicity studies in rats, rabbits, and mice. Cong Anom Kyoto 37:47-138. (Pubitemid 127080760)
20. Nau H. 1986. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 33:21-27.
21. Nau H, Siemens H. 1992. Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Pharm Weekbl Sci 14:101-107.
22. Nau H, Hauck RS, Ehlers K. 1991. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69:310-321.
23. Okada A, Fujiwara M. 2006. Molecular approaches to developmental malformations using analogous forms of valproic acid. Congenit Anom Kyoto 46:68-75. (Pubitemid 43752226)
24. Okada A, Kurihara H, Aoki Y, Bialer M, Fujiwara M. 2004. Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defects Res Part B Dev Reprod Toxcol 71:47-53. (Pubitemid 38327867)
25. Okada A, Onishi Y, Aoki Y, Yagen B, Sobol E, Bialer M, Fujiwara M. 2006. Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defects Res Part B Dev Reprod Toxcol 77:227-233. (Pubitemid 43955627)
26. Okada A, Onishi Y, Yagen B, Shimshoni JA, Kaufmann D, Bialer M, Fujiwara M. 2008. Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice. Birth Defects Res Part A Clin Mol Teratol 82:610-621.
27. Ong LL, Schardein JL, Petrere JA, Sakowski R, Jordan H, Humphrey RR, Fitzgerald JE, de la Iglesia FA. 1983. Teratogenesis of calcium valproate in rats. Fundam Appl Toxicol 3:121-126.
28. Pessah N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. 2009. α-Fluoro-2,2,3,3-tertamethyelcylcopropanecarboxamide a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J Med Chem 52:2233-2244.
29. Petrere JA, Anderson JA, Sakowski R, Fitzgerald JE, de la Iglesia FA. 1986. Teratogenesis of calcium valproate in rabbits. Teratology 34:263-269.
30. Rogers JM, Setzer RW, Branch S, Chernoff N. 2004. Chemically induced supernumerary lumbar ribs in CD-1 mice: Size distribution and dose response. Birth Defects Res Part B Dev Reprod Toxcol 71:17-25. (Pubitemid 38327864)
31. Shimshoni AJ, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. 2007. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J Med Chem 50:6419-6427. (Pubitemid 350250429)
32. Shimshoni AJ, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M 2008. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid. Epilepsia 49:1202-1212. (Pubitemid 351991399)
33. Sobol E, Bialer M, Yagen B. 2004. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J Med Chem 47:4316-4326. (Pubitemid 39045437)
34. Sobol E, Yagen B, White HS,Wilcox KS, Lamb JG, Pappo O,Wlodarczyk BJ, Finnell RH, Bialer M. 2006. Preclinical evaluation of 2,2,3,3- tetramethylcyclopropanecarbonylurea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology 51:933-946.
35. Spielman MA, Geiszler AO, Close WJ. 1948. Anticonvulsant drugs, II. Some acetyureas. J Am Chem Soc 70:4189-4191.
36. Stoughton RW, Dickison HL, Fitzhugh G. 1939. Diacetylureas. II. Preparation and properties of diacyl ureas derived from branched aliphatic acids. JACS 61:408-410.
37. Tantisira B, Tantisira MH, Patarapanich C, Sooksawate T, Chunngam T. 1997. Preliminary evaluation of anticonvulsant activity of a valproic acid analogue: N-(2-propylpentanoyl) urea. Res Commun Mol Pathol Pharmacol 97:151-164. (Pubitemid 27430543)
38. Vorhees CV. 1987. Teratogenicity and developmental toxicity of valproic acid in rats. Teratology 35:195-202. (Pubitemid 17072912)
39. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. 2002. Discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic Drugs, 5th ed. New York: Lippincott Williams & Wilkins Publishers. p 36-48.